Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Michael J. Baine

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1163-7539; OpenAlex author ID A5006831359; NIH RePORTER profile ID 10891723. Sources: OpenAlex.

Their work

Papers
25 (first author 10, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
50
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers, 1 grant · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 25

  1. radioGWAS links radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer. Co-author DOI 10.1038/s41598-024-62741-5↗
  2. 3DGAUnet: 3D Generative Adversarial Networks with a 3D U-Net Based Generator to Achieve the Accurate and Effective Synthesis of Clinical Tumor Image Data for P… Co-author DOI 10.3390/cancers15235496↗
  3. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2021.12.018↗
  4. Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications. Co-author DOI 10.3390/cancers14071654↗
  5. The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change? Co-author DOI 10.1016/j.ctro.2021.04.002↗
  6. Effects of interobserver and interdisciplinary segmentation variabilities on CT-based radiomics for pancreatic cancer. First author DOI 10.1038/s41598-021-95152-x↗
  7. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. First author DOI 10.1016/j.ctro.2020.06.003↗
  8. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. First author DOI 10.1186/s12885-020-07016-8↗
  9. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective anal… First author DOI 10.1186/s13014-020-01569-5↗
  10. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National… First author DOI 10.3389/fonc.2020.01518↗
  11. Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers12041051↗
  12. Incidence and Patterns of Locoregional Failure After Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.prro.2018.06.006↗
  13. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced panc… First author DOI 10.1186/s12885-019-6220-1↗
  14. Biological determinants of radioresistance and their remediation in pancreatic cancer. First author DOI 10.1016/j.bbcan.2017.02.003↗
  15. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Co-author DOI 10.1038/onc.2014.154↗
  16. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. First author DOI 10.1038/bjc.2014.385↗
  17. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-2174↗
  18. Quantitative real-time PCR expression analysis of peripheral blood mononuclear cells in pancreatic cancer patients. Co-author DOI 10.1007/978-1-62703-287-2_8↗
  19. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  20. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Co-author DOI 10.1186/1756-8722-5-68↗
  21. Early diagnosis of pancreatic cancer: challenges and new developments. First author DOI 10.2217/bmm.12.69↗
  22. Current status of molecular markers for early detection of sporadic pancreatic cancer. First author DOI 10.1016/j.bbcan.2010.09.002↗
  23. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. Co-author DOI 10.1371/journal.pone.0017014↗
  24. Marital status and survival in pancreatic cancer patients: a SEER based analysis. Co-author DOI 10.1371/journal.pone.0021052↗
  25. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Co-author DOI 10.3233/cbm-2012-0260↗

Grants 1

  1. Mechanistic Studies of MUC4 and NGAL in Pancreatic Adenocarcinoma F31CA165885↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chi H. Lin · 13 shared papers, 2011–2022 · strength 1.70
  2. Michael Anthony Hollingsworth · 6 shared papers, 2014–2024 · strength 0.79
  3. Dandan Zheng · 5 shared papers, 2020–2024 · strength 0.75
  4. Jane L. Meza · 4 shared papers, 2020 · strength 0.62
  5. Saber Amin · 4 shared papers, 2020 · strength 0.62
  6. Hongfeng Yu · 3 shared papers, 2022–2024 · strength 0.52
  7. Surinder K. Batra · 12 shared papers, 2011–2017 · strength 0.46
  8. Lynette M. Smith · 7 shared papers, 2011–2022 · strength 0.39
  9. Chi Zhang · 2 shared papers, 2023–2024 · strength 0.37
  10. Bradley Norman Reames · 2 shared papers, 2021–2022 · strength 0.33
  11. Kiersten Preuss · 2 shared papers, 2022–2024 · strength 0.33
  12. Jeffrey Wong · 2 shared papers, 2021–2024 · strength 0.31
  13. Sukhwinder Kaur · 8 shared papers, 2011–2017 · strength 0.31
  14. Maneesh Jain · 6 shared papers, 2012–2017 · strength 0.24
  15. Yu Shi · 1 shared paper, 2023 · strength 0.19
  16. Chunmeng Zhang · 1 shared paper, 2022 · strength 0.19
  17. Kavita B. Mallya · 5 shared papers, 2011–2014 · strength 0.18
  18. Yu Shi · 1 shared paper, 2024 · strength 0.18
  19. Paul M. Grandgenett · 1 shared paper, 2024 · strength 0.18
  20. Satyanarayana Rachagani · 5 shared papers, 2011–2015 · strength 0.17
  21. Richard L. Sleightholm · 1 shared paper, 2019 · strength 0.16
  22. Subhankar Chakraborty · 5 shared papers, 2011–2013 · strength 0.16
  23. William Adrian Hall · 1 shared paper, 2021 · strength 0.15
  24. Jeffrey M. Ryckman · 1 shared paper, 2021 · strength 0.15
  25. Justin A. Chen · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.